Bulevirtide monotherapy for 48 weeks in patients with HDV-related compensated cirrhosis and clinically significant portal hypertension
- 13 August 2022
- journal article
- research article
- Published by Elsevier BV in Journal of Hepatology
- Vol. 77 (6), 1525-1531
- https://doi.org/10.1016/j.jhep.2022.07.016
Abstract
No abstract availableKeywords
Funding Information
- Agence Nationale de la Recherche (ANR-17-RHUS-0003)
- Ministero della Salute (RC2021/105-01)
This publication has 26 references indexed in Scilit:
- Serum hepatitis B core-related antigen (HBcrAg) correlates with covalently closed circular DNA transcriptional activity in chronic hepatitis B patientsJournal of Hepatology, 2019
- EASL Clinical Practice Guidelines: Management of hepatocellular carcinomaJournal of Hepatology, 2018
- Final results of a multicenter, open-label phase 2b clinical trial to assess safety and efficacy of Myrcludex B in combination with Tenofovir in patients with chronic HBV/HDV co-infectionJournal of Hepatology, 2018
- EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infectionJournal of Hepatology, 2017
- EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosisJournal of Hepatology, 2015
- Expanding consensus in portal hypertensionJournal of Hepatology, 2015
- Competing risks and prognostic stages of cirrhosis: a 25‐year inception cohort study of 494 patientsAlimentary Pharmacology & Therapeutics, 2014
- Elastography, Spleen Size, and Platelet Count Identify Portal Hypertension in Patients With Compensated CirrhosisGastroenterology, 2013
- Determination of reliability criteria for liver stiffness evaluation by transient elastographyJournal of Hepatology, 2012
- Serum activity of alanine aminotransferase (ALT) as an indicator of health and diseaseJournal of Hepatology, 2008